Satralizumab
Phase 3Recruiting 0 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
NMDAR Autoimmune Encephalitis
Conditions
NMDAR Autoimmune Encephalitis, LGI1 Autoimmune Encephalitis
Trial Timeline
Sep 27, 2022 → Dec 14, 2029
NCT ID
NCT05503264About Satralizumab
Satralizumab is a phase 3 stage product being developed by Chugai Pharmaceutical for NMDAR Autoimmune Encephalitis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05503264. Target conditions include NMDAR Autoimmune Encephalitis, LGI1 Autoimmune Encephalitis.
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05503264 | Phase 3 | Recruiting |
| NCT05271409 | Phase 3 | Recruiting |
| NCT04963270 | Phase 3 | Terminated |